Therapeutic Vaccines: The Global Market

April 16, 2010

Wellesley, Mass. – According to a new technical market research report, THERAPEUTIC VACCINES: THE GLOBAL MARKET (BIO052B) from BCC Research (www.bccresearch.com), the global market value for therapeutic vaccines is an estimated $137 million in 2010, but is expected to increase to nearly $3.1 billion in 2014, for a 4-year compound annual growth rate (CAGR) of 117.7%.

The largest segment in the market, cancer vaccine products, is expected to increase at a 4-year CAGR of 115.3%, from $137 million in 2010 to $2.9 billion in 2014.

The other segment in the market, addictions vaccine products, is expected to see no revenue until 2013, at about $77 million. That is expected to increase to $135 million in 2014.

Therapeutic vaccines are products that treat existing diseases or conditions. The primary technology involved stimulates natural mechanisms of the immune system to overpower an already present infection or disease. In this sense, they are considered therapies, not preventive agents (i.e., traditional prophylactic vaccines).

To Contact us, click here  

A period of dynamic growth in the therapeutic vaccines market is expected with the rollout of some eight products before 2015, not only to treat cancer but to address nicotine addiction as well. Various approaches are being used to develop vaccines that boost the immune response to cancerous cells.  Further back in the pipeline, therapeutic vaccines are also in development to treat infectious diseases such as the human immunodeficiency virus (HIV) and hepatitis C (HCV), neurological disorders such as Alzheimer’s disease, autoimmune disorders such as rheumatoid arthritis and multiple sclerosis, and other conditions such as hypertension.

At the beginning of 2010, there only were two participants with dedicated therapeutic vaccines actively being sold on the worldwide market. Therefore, the emphasis of this report is on the 113 therapeutic vaccines in various stages of development, the companies poised to introduce products during the forecast period, and how these introductions will play out in terms of the competitive environment.

BCC has compiled a detailed description of therapeutic vaccines in phase 1, 2, and 3 stages of clinical development.  The study includes technological descriptions and challenges, applications, major players, international aspects, and projected growth for some of these therapeutic vaccines through 2014. This report will be of interest to members of the pharmaceutical, healthcare, and biotechnology industries. It also will be a valuable resource for investors in the biotechnology and pharmaceutical sectors. It is written in such a way as to be accessible to the businessperson while maintaining a high level of technical detail.

Therapeutic Vaccines: The Global Market( BIO052B )
Publish Date: Mar 2010    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.